Category: News
Leveraged Finance & Private Equity Communities Unite to Raise Record $3 Million for Melanoma Research
21 June 2022 In Allies & Partnerships, Events, News, Prevention
On Thursday, June 16, 2022, more than 900 people from over 100 firms from the leveraged finance and private equity communities came together for the Leveraged Finance Fights Melanoma (LFFM) benefit and cocktail party. Hosted at the Museum of Modern Art, the event raised a record breaking $3 million for the Melanoma Research Alliance’s (MRA) mission to advance the world’s most innovative and promising melanoma research.
MRA Announces $13 Million in Grants to Advance Melanoma Prevention, Detection & Treatment
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 19 May 2022 In News, Prevention, Science, Treatment
Coinciding with Melanoma Awareness Month, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced funding for 27 research grants totaling $13,046,774 to support new research aimed at advancing melanoma prevention, diagnosis and treatment.
The Melanoma Research Alliance Names Dr. Marc Hurlbert as Chief Executive Officer
11 May 2022 In Allies & Partnerships, News
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced that its Board of Directors appointed Marc Hurlbert, PhD, as its new Chief Executive Officer.
A Message from the Melanoma Research Alliance
21 April 2022 In News
Michael Kaplan, MRA’s President & CEO, will retire on April 30, 2022. Kaplan, who has led the Melanoma Research Alliance since 2016, will be succeeded by Dr. Marc Hurlbert.
Unlocking the Potential of Localized Treatments By Better Understanding Treatment Response
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 23 March 2022 In News, Science, Treatment
It’s easy to think of melanoma – or any cancer – in black and white terms. You have it or you don’t, it responds or it’s resistant to treatment, or it grows or it shrinks. However, like most things, the reality is far more complex.
MRA Applauds Approval of Relatlimab + Nivolumab for the Treatment of Advanced Melanoma
18 March 2022 In News, Science, Treatment
The Melanoma Research Alliance (MRA) welcomed the news today that the U.S. Food & Drug Administration (FDA) has approved Opdualag™, Bristol-Myers Squibb’s new combination immunotherapy for the treatment of advanced melanoma.
Recordings from MRA's 2022 Patient Forum
16 March 2022 In Allies & Partnerships, Events, Melanoma Stories, News, Policy, Prevention, Science, Treatment
MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022, brought together hundreds of melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.
New Research Says Combination Immunotherapy Should be First-Line Therapy for Patients with BRAF-mutant Melanoma
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 2 February 2022 In News, Science, Treatment
While all patients with advanced melanoma can be treated with checkpoint immunotherapies, patients with tumors containing the BRAF mutation can also be treated with targeted therapies. However, until now, doctors have had little prospective data to determine which treatment approach should be started first. A new study led by Dr. Michael Atkins provides practice-changing insight.
Melanoma Mortality Rate Continues Decline Fueled by Treatment Advances
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 26 January 2022 In News, Prevention, Science, Treatment
Each January, the American Cancer Society (ACS) releases updated estimates about trends in new cancer cases and deaths in its annual report, Cancer Facts and Figures. This report highlights the estimated incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for cancer in the United States.
MRA Celebrates Approval of Tebentafusp - First Drug for Metastatic Uveal Melanoma
By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 26 January 2022 In News, Treatment
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, applauds the U.S. Food and Drug Administration (FDA) decision to approve the first-ever therapy for metastatic or unresectable uveal melanoma.